Skip to main content
SpringerLink
Log in

The response of pancreatic acinar cell carcinoma to platinum and olaparib therapy in a germline BRCA2 variant carrier: case report and literature review

  • Brief Report
  • Published:
Familial Cancer Aims and scope Submit manuscript

Abstract

A 73-year-old Japanese man with a history of distal biliary cancer treated by pancreatoduodenectomy developed pancreatic acinar cell carcinoma (PACC) treated by remnant pancreatectomy and adjuvant chemotherapy. Thirteen months after surgery, multiple liver metastases developed and FOLFOX chemotherapy was initiated. Based on the PACC diagnosis and a positive family history for breast and ovarian cancer genetic testing was performed which revealed a pathogenic germline BRCA2 variant (c.8629G > T, p.Glu2877Ter). Olaparib therapy was initiated and the metastases responded well (partial response). PACC is a BRCA2-associated cancer which may respond well to PARP inhibitors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Data availability

The data that support the findings of this study are available from the corresponding author (H.M.) upon reasonable request.

References

  1. Wood LD, Klimstra DS (2014) Pathology and genetics of pancreatic neoplasms with acinar differentiation. Semin Diagn Pathol 31:491–497

    Article  PubMed  PubMed Central  Google Scholar 

  2. Calimano-Ramirez LF, Daoud T, Gopireddy DR et al (2022) Pancreatic acinar cell carcinoma: a comprehensive review. World J Gastroenterol 28:5827–5844

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Matsubayashi H, Todaka A, Kawakami T et al (2023) Genetic medicine in companion diagnostics of germline BRCA testing of Japanese pancreatic cancer patients. J Hum Genet 68:81–86

    Article  CAS  PubMed  Google Scholar 

  4. Mizukami K, Iwasaki Y, Kawakami E et al (2020) Genetic characterization of pancreatic cancer patients and prediction of carrier status of germline pathogenic variants in cancer-predisposing genes. EBioMedicine 60:103033

    Article  PubMed  PubMed Central  Google Scholar 

  5. Furukawa T, Sakamoto H, Takeuchi S et al (2015) Whole exome sequencing reveals recurrent mutations in BRCA2 and FAT genes in acinar cell carcinomas of the pancreas. Sci Rep 5:8829

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Lee CL, Holter S, Borgida A et al (2022) Germline BRCA2 variants in advanced pancreatic acinar cell carcinoma: a case report and review of literature. World J Gastroenterol 28:6421–6432

    Article  PubMed  PubMed Central  Google Scholar 

  7. Mandelker D, Marra A, Zheng-Lin B et al (2023) Genomic profiling reveals germline predisposition and homologous recombination deficiency in pancreatic acinar cell carcinoma. J Clin Oncol 41:5151–5162

    Article  CAS  PubMed  Google Scholar 

  8. Lelong M, Raoul JL, Touchefeu Y et al (2022) Prolonged response on olaparib maintenance in metastatic pancreatic acinar cell carcinoma associated with a germline BRCA 2 mutation, revealed by severe panniculitis. Clin Case Rep 10:e6718

    Article  PubMed  PubMed Central  Google Scholar 

  9. Li M, Mou Y, Hou S et al (2018) Response of germline BRCA2-mutated advanced pancreatic acinar cell carcinoma to olaparib: a case report. Medicine (Baltimore) 97:e13113

    Article  PubMed  Google Scholar 

  10. Xu JY, Guan WL, Lu SX et al (2022) Optimizing chemotherapy of pancreatic acinar cell carcinoma: our experiences and pooled analysis of literature. Clin Med Insights Oncol 16:11795549221090186

    Article  PubMed  PubMed Central  Google Scholar 

  11. Takahashi H, Ikeda M, Shiba S et al (2021) Multicenter retrospective analysis of chemotherapy for advanced pancreatic acinar cell carcinoma: potential efficacy of platinum- and irinotecan-containing regimens. Pancreas 50:77–82

    Article  PubMed  Google Scholar 

  12. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–47

  13. Robson M, Im SA, Senkus E et al (2017) Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 377:523–533

    Article  CAS  PubMed  Google Scholar 

  14. Mirza MR, Monk BJ, Herrstedt J et al (2016) Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 375:2154–2164

    Article  CAS  PubMed  Google Scholar 

  15. Golan T, Hammel P, Reni M et al (2019) Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med 381:317–327

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Sunami T, Yamada A, Kondo T et al (2022) Exceptional response of pancreatic acinar cell carcinoma and bile duct cancer to platinum-based chemotherapy in a family with a germline BRCA2 variant. Pancreas 51:1258–1262

    Article  CAS  PubMed  Google Scholar 

  17. Okusaka T, Nakamura M, Yoshida M et al (2023) Clinical practice guidelines for pancreatic cancer 2022 from the japan pancreas society: a synopsis. Int J Clin Oncol 28:493–511

    Article  PubMed  PubMed Central  Google Scholar 

  18. Golan T, O’Kane GM, Denroche RE et al (2021) Genomic features and classification of homologous recombination deficient pancreatic ductal adenocarcinoma. Gastroenterology 160(2119–2132):e9

    Google Scholar 

  19. Florou V, Elliott A, Bailey MH et al (2023) Comparative genomic analysis of pancreatic acinar cell carcinoma (PACC) and pancreatic ductal adenocarcinoma (PDAC) unveils new actionable genomic aberrations in PACC. Clin Cancer Res 29:3408–3417

    Article  CAS  PubMed  Google Scholar 

  20. Dreikhausen L, Schulte N, Belle S et al (2021) Pancreatic acinar cell carcinoma with germline BRCA2 mutation and severe pancreatic panniculitis: a case report. Visc Med 37:447–450

    Article  PubMed  PubMed Central  Google Scholar 

  21. Okawa Y, Iwasaki Y, Johnson TA et al (2023) Hereditary cancer variants and homologous recombination deficiency in biliary tract cancer. J Hepatol 78:333–342

    Article  CAS  PubMed  Google Scholar 

  22. Ueki A, Yoshida R, Kosaka T et al (2023) Clinical risk management of breast, ovarian, pancreatic, and prostatic cancers for BRCA1/2 variant carriers in Japan. J Hum Genet 68:517–526

    Article  CAS  PubMed  Google Scholar 

  23. Momozawa Y, Sasai R, Usui Y et al (2022) Expansion of cancer risk profile for BRCA1 and BRCA2 pathogenic variants. JAMA Oncol 8:871–878

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank Eigo Eibun Tensaku Center for English language editing.

Funding

This study was supported by JSPS KAKENHI (Grant Number 19K19372 to K.Y.).

Author information

Authors and Affiliations

  1. Division of Genetic Medicine Promotion, Shizuoka Cancer Center, 1007, Shimonagakubo, Nagaizumi, Suntogun, Shizuoka, 411-8777, Japan

    Hiroyuki Matsubayashi, Yoshimi Kiyozumi, Rina Harada, Eiko Ishihara & Satomi Higashigawa

  2. Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan

    Hiroyuki Matsubayashi, Hiroki Sakamoto, Junya Sato & Hirotoshi Ishiwatari

  3. Division of Medical Oncology and Hematology, Faculty of Medicine, Oita University, Oita, Japan

    Akiko Todaka

  4. Division of GI Oncology, Shizuoka Cancer Center, Shizuoka, Japan

    Takahiro Tsushima

  5. Division of Pathology, Shizuoka Cancer Center, Shizuoka, Japan

    Nobuyuki Ohike

  6. Hepato-Biliary-Pancreatic Surgery of Shizuoka Cancer Center, Shizuoka, Japan

    Teichi Sugiura & Katsuhiko Uesaka

Authors
  1. Hiroyuki Matsubayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Akiko Todaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takahiro Tsushima
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yoshimi Kiyozumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rina Harada
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Eiko Ishihara
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Satomi Higashigawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Nobuyuki Ohike
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hiroki Sakamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Junya Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Hirotoshi Ishiwatari
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Teichi Sugiura
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Katsuhiko Uesaka
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conception of the work: H.M, Y.K, writing manuscript: H.M; data acquisition: A.T, T.T, H.S, J. S, H.I, T.S, K.U; evaluation of genetic variant: R.H, E.I; and pathological interpretation: N.O. All authors have approved the final manuscript.

Corresponding author

Correspondence to Hiroyuki Matsubayashi.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Consent for publication

A written informed consent for the publication was obtained from the patient.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Matsubayashi, H., Todaka, A., Tsushima, T. et al. The response of pancreatic acinar cell carcinoma to platinum and olaparib therapy in a germline BRCA2 variant carrier: case report and literature review. Familial Cancer (2024). https://doi.org/10.1007/s10689-024-00390-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s10689-024-00390-3

Keywords

Search

Navigation